Core Insights - Recursion, a clinical stage TechBio company, will present new clinical data from the ongoing TUPELO Phase 1b/2 trial of REC-4881 for Familial Adenomatous Polyposis (FAP) during a webinar on December 8, 2025 [1][2] - The company utilizes a platform called Recursion OS, which integrates various technologies to create one of the largest proprietary biological and chemical datasets, enabling advanced drug discovery [3] Company Overview - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry, with additional offices in Montréal, New York, London, and Oxford [4] - The company focuses on decoding biology to improve lives, leveraging machine-learning algorithms to analyze vast datasets and conduct millions of wet lab experiments weekly [3] Leadership and Presenters - The webinar will feature key personnel including Najat Khan, Ph.D. (Chief R&D and Chief Commercial Officer), David Mauro, M.D., Ph.D. (Chief Medical Officer), and other notable experts [6]